News
Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium
Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium 6 August 2024 – Osaka, Japan – Santen Pharmaceutical
CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US
We are proud to announce that CBT-004, a potential first-in-class drug for vascularised pinguecula, has completed the first patient-in for Phase 2 clinical trials in
Remarkable Progress in Clinical Trials: CBT-009 and CBT-004
We are proud to announce that CBT-009, our novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia, has reached agreement with FDA
Seeing Life Better Through Medicine
Imagine a world where everyone can experience the joy and beauty of clear vision. At Cloudbreak, our mission is centered around the belief that vision
Cloudbreak: A Clinical-Stage Company Dedicated to Improving Vision Health
Perhaps you are unfamiliar with us and unsure of what motivates us to become a mission-driven company. Today, we are excited to share our story
Cloudbreak Pharma Named a Potential Unicorn for 2023
On June 20th, 2023, Greatwall Strategy Consultants (GEI) released the “2023 China Potential Unicorns Research Report”. Cloudbreak Pharma is honoured to be named one
